P.E.A. Endocannabinoid Support

AOR Advanced Orthomolecular Research Advanced

#Other

Safety78

Efficacy68

Transparency62

Based on Examine, Wikipedia, and 23 other sources

Overview

This product features Palmitoylethanolamide (PEA) at a dosage that aligns with effective levels shown in clinical research, which is a strong indicator of its potential effectiveness in modulating the endocannabinoid system, reducing inflammation, and alleviating pain. The 'Micronized' form of PEA is noted on the label, which often suggests improved bioavailability. The product's claim of being the first PEA product with a Health Canada Natural Product Number (NPN) offers a measure of regulatory oversight and quality assurance.

The Good

Optimal Dosing of PEA: The product offers PEA in dosages (400mg and 1200mg) that align with clinically effective ranges, supporting its potential for pain and inflammation relief.

Good Safety Profile: Palmitoylethanolamide is generally well-tolerated with very few reported side effects.

Strong Regulatory Assurance: Being the first PEA product with a Health Canada NPN indicates adherence to rigorous quality and safety standards.

The Bad

Duplicate Ingredient Listing: The supplement facts panel shows 'Palmitoylethanolamide' listed twice at different amounts (1200mg and 400mg per serving), which is confusing and unclear if these are per-capsule doses or different product variations.

Lack of Specific Micronization Details: While 'micronized' is mentioned, the specific type or degree of micronization is not detailed, which could impact bioavailability.

General Precautions: The caution for use beyond 40 days and general warnings for specific populations necessitate healthcare practitioner consultation, which might be a barrier for some users.